Version of Record online: 20 SEP 2004
Volume 17, Issue 5, pages 409–426, October 2004
How to Cite
Winterfield, L. S. and Menter, A. (2004), Infliximab. Dermatologic Therapy, 17: 409–426. doi: 10.1111/j.1396-0296.2004.04044.x
- Issue online: 20 SEP 2004
- Version of Record online: 20 SEP 2004
- psoriatic arthritis
ABSTRACT: Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-α in the immunopathogenesis of psoriatic disease. This review summarizes the current data regarding the use of infliximab in treating psoriasis and psoriatic arthritis, as well as the safety data available from patients with other immune-mediated inflammatory disorders. Practical issues such as patient selection, monitoring, cost, and potential combination therapies are also discussed.